多巴胺药物对帕金森病中抑郁症症状尺寸的分离效应
Harry Costello1, Anette-Eleonore Schrag2, Robert Howard3
1Institute of Cognitive Neuroscience, University College London, London, UK.
medRxiv : the preprint server for health sciences
|July 10, 2023
概括
多巴胺激动剂可以改善帕金森病 (PD) 抑郁症的动机症状,而MAO-B抑制剂可以帮助抑郁和动机症状. 治疗效果随着疾病的进展而变化.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症在帕金森病 (PD) 中是常见的和致残的,通常对标准治疗反应不佳.
- 在PD抑郁症中,像冷漠和无情感这样的激励症状很普遍,并预测治疗抵抗力.
- 在PD中,多巴氨基系统功能障碍与动机症状和情绪波动有关.
结论:
- 多巴胺类药物对PD的不同抑郁层面具有可分离的作用.
- 多巴胺激动剂显示出治疗PD抑郁症的动机症状的潜力.
- MAO-B 抑制剂可以改善抑郁和动机症状,对动机的影响取决于疾病的严重程度.
相关概念视频
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Parkinson's Disease: Overview
604
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
604
Antidepressant Drugs: MAOIs and Other Agents
275
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
275
Depressive Disorders: MDD and Dysthymia
176
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
176
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
405
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
405


